Actively Recruiting
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-03-06
120
Participants Needed
1
Research Sites
163 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.
CONDITIONS
Official Title
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and agree to participate in the study with good compliance
- Aged between 18 and 75 years old
- Have advanced solid tumors confirmed to have RAS mutations or amplifications and have failed standard treatment
- ECOG performance status score of 0 or 1
- Life expectancy greater than 3 months
- At least one measurable tumor lesion according to RECIST v1.1
- Adequate organ function
You will not qualify if you...
- Unrecovered toxicity from prior anti-tumor treatments worse than Grade 1 or as specified
- Presence of central nervous system metastases
- Gastrointestinal diseases affecting drug administration or absorption
- Major surgery within 28 days before first dose or expected during the study
- Serious pulmonary diseases
- Active or recent (within 48 weeks) active tuberculosis infection
- Active or persistent gastrointestinal bleeding within 6 months
- History of allogeneic bone marrow or solid organ transplantation
- History of deep vein thrombosis or pulmonary embolism within 6 months
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring intervention
- Positive HIV test or active chronic hepatitis B or C infection
- Known allergy to any component of the study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300181
Actively Recruiting
Research Team
R
Rongfu Mao
CONTACT
J
Jizhao Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here